Literature DB >> 25695918

Necrotizing myopathies: an update.

Colin Quinn1, Johnny S Salameh, Thomas Smith, Nizar Souayah.   

Abstract

Necrotizing myopathy is defined by the predominant pathological feature of necrosis of muscle fibers in the absence of substantial lymphocytic inflammatory infiltrates. Most commonly necrotizing myopathies are divided into immune mediated (IMNM) and nonimmune mediated (NIMNM). IMNM has been associated with anti-signal recognition particle antibodies, connective tissue diseases, cancer, post-statin exposure with 3-hydroxy-3-methylglutaryl-coenzyme A antibodies, and viral infections including HIV and hepatitis C. NIMNM is linked to medications and toxic exposures. Both IMNM and NIMNM are typically characterized by proximal weakness, although the severity can vary substantially. Myalgias are reported by some, but not all, patients. Pathological findings on muscle biopsy include predominant fiber necrosis with little or no inflammatory infiltrate. In IMNM, there is variable evidence for the deposition of membrane attack complex on capillaries and muscle fibers, although membrane attack complex deposition on capillaries is typically less than is seen in dermatomyositis; class I major histocompatibility complex expression on muscle fibers is variable but typically less than is seen in polymyositis. Immunohistochemical abnormalities are not typically seen in NIMNM. Treatment of IMNM involves immunosuppressive therapy, although there are no controlled trials to guide particular treatment choices. Treatment of NIMNM involves removal of the toxic exposure.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25695918     DOI: 10.1097/CND.0000000000000065

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  8 in total

Review 1.  Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.

Authors:  Pari Basharat; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.592

2.  Therapeutic management of immune-mediated necrotizing myositis.

Authors:  Emma Weeding; Eleni Tiniakou
Journal:  Curr Treatm Opt Rheumatol       Date:  2021-03-29

Review 3.  Corticosteroids in Myositis and Scleroderma.

Authors:  Anna Postolova; Jennifer K Chen; Lorinda Chung
Journal:  Rheum Dis Clin North Am       Date:  2015-10-26       Impact factor: 2.670

Review 4.  Myopathy associated with anti-signal recognition particle antibodies with pulmonary involvement and response to rituximab.

Authors:  Carolina Mazeda; Rita Cunha; Pedro Gonçalo Ferreira; Anabela Barcelos; Renata Aguiar
Journal:  Rheumatol Int       Date:  2021-06-04       Impact factor: 2.631

5.  Muscle aches and pains: do I have leukemia?

Authors:  Max Deschner; Chai Phua; Lalit Saini; Anargyros Xenocostas; Uday Deotare
Journal:  Int J Hematol       Date:  2019-10-14       Impact factor: 2.319

6.  Reply to "Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?".

Authors:  David S Fedson; Jeffrey R Jacobson; Ole Martin Rordam; Steven M Opal
Journal:  mBio       Date:  2016-02-23       Impact factor: 7.867

7.  Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?

Authors:  Viroj Wiwanitkit
Journal:  mBio       Date:  2016-02-23       Impact factor: 7.867

8.  Atorvastatin-induced necrotizing autoimmune myositis: An emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype.

Authors:  Yves Troyanov; Océane Landon-Cardinal; Marvin J Fritzler; José Ferreira; Ira N Targoff; Eric Rich; Michelle Goulet; Jean-Richard Goulet; Josiane Bourré-Tessier; Yves Robitaille; Julie Drouin; Alexandra Albert; Jean-Luc Senécal
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.